Medical Technology Company Heru, Inc. Completes FDA Registration Following a $2.7M Seed Round
Summary
The funding facilitates the completion of current clinical trials for FDA clearance of Heru’s wearable AI platform and subsequent commercialization efforts. According to JAMA Ophthalmology, more than 50M patients in the U.S. experience visual field defects and strabismus from glaucoma, stroke(s), age-related macular degeneration (AMD), diabetes, and retinitis pigmentosa (450M worldwide). Heru’s convenient, accurate, and validated AI software platform is ideally positioned to enable exponential access and scale for critical eye health diagnostics, screening, and visual augmentation for these patients. Heru’s AI platform was developed by the leading minds in ophthalmology from Bascom Palmer Eye Institute to alleviate significant bottlenecks and gaps in current patient care. There is no need for dedicated exam rooms; technicians and patients alike can do tests in any setting (clinic, pharmacy, home), growingly more critical in today’s current environment.
Funding
Review available funding amount, funding date, investors, and linked company information related to Medical Technology Company Heru, Inc. Completes FDA Registration Following a $2.7M Seed Round in the interactive ISVWorld profile.